Method for treating ifnalpha related conditions

Abstract

An immunogenic product including IFNα coupled to a carrier protein molecule is capable to induce in vivo anti-IFNα antibodies and is useful in treating IFNα related conditions.

1 - 3 . (canceled) 
     
     
         4 . A method for treating an IFNα related condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an immunogenic product comprising IFNα coupled to a carrier protein molecule, wherein said therapeutically effective amount is more than 30 mcg of immunogenic product per administration. 
     
     
         5 . The method according to  claim 4 , wherein the administration of the therapeutically effective amount of the immunogenic product prevents the occurrence of symptoms of a disease linked to an over-production of IFNα. 
     
     
         6 . The method according to  claim 4 , wherein the administration of the therapeutically effective amount of the immunogenic product prevents the flare of a disease linked to an over-production of IFNα. 
     
     
         7 . The method according to  claim 4 , wherein the IFNα related condition is selected from the group comprising systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjögren syndrome, vasculitis, HIV, type I diabetes, autoimmune thyroiditis and myositis. 
     
     
         8 . The method according to  claim 4 , wherein the therapeutically effective amount of the immunogenic product is from 35 mcg to 1000 mcg of immunogenic product per administration. 
     
     
         9 . The method according to  claim 4 , wherein the immunogenic product is administrated to the subject at least twice in a month. 
     
     
         10 . The method according to  claim 9 , wherein the immunogenic product is further administrated to the subject at least once every three months. 
     
     
         11 . The method according to  claim 9 , wherein the immunogenic product is further administrated to the subject when, in a serum sample obtained from the subject, the amount of anti-IFNα antibodies is undetectable. 
     
     
         12 . The method according to  claim 4 , wherein the immunogenic product is strongly inactivated, which means that the product shows less than 5% of antiviral activity in the conditions of TEST B. 
     
     
         13 . The method according to  claim 4 , wherein the immunogenic product is capable of neutralizing the antiviral activity of IFNα in the conditions of TEST C. 
     
     
         14 . The method according to  claim 4 , wherein the immunogenic product comprises at least one subtype of IFNα. 
     
     
         15 . The method according to  claim 4 , wherein the immunogenic product comprises the subtype IFNα 2b of IFNα and wherein the carrier protein molecule is KLH. 
     
     
         16 . The method according to  claim 4 , wherein the immunogenic product is a vaccine, preferably in the form of an emulsion. 
     
     
         17 . A unit dosage form comprising more than 30 mcg of an immunogenic product comprising IFNα coupled to a carrier protein molecule. 
     
     
         18 . A medical device comprising more than 30 mcg of an immunogenic product comprising IFNα coupled to a carrier protein molecule. 
     
     
         19 . A kit comprising at least one vial containing more than 30 mcg of an immunogenic product comprising IFNα coupled to a carrier protein molecule, at least one vial containing adjuvant, and means for contacting said immunogenic product to the adjuvant, and for emulsifying the mixture with the adjuvant.